443 related articles for article (PubMed ID: 36195833)
1. Identification and validation of a fatty acid metabolism-related lncRNA signature as a predictor for prognosis and immunotherapy in patients with liver cancer.
Chen E; Yi J; Jiang J; Zou Z; Mo Y; Ren Q; Lin Z; Lu Y; Zhang J; Liu J
BMC Cancer; 2022 Oct; 22(1):1037. PubMed ID: 36195833
[TBL] [Abstract][Full Text] [Related]
2. Identification of m6A methyltransferase-related lncRNA signature for predicting immunotherapy and prognosis in patients with hepatocellular carcinoma.
Li L; Xie R; Lu G
Biosci Rep; 2021 Jun; 41(6):. PubMed ID: 34027555
[TBL] [Abstract][Full Text] [Related]
3. Identification and characterization of a 25-lncRNA prognostic signature for early recurrence in hepatocellular carcinoma.
Fu Y; Wei X; Han Q; Le J; Ma Y; Lin X; Xu Y; Liu N; Wang X; Kong X; Gu J; Tong Y; Wu H
BMC Cancer; 2021 Oct; 21(1):1165. PubMed ID: 34717566
[TBL] [Abstract][Full Text] [Related]
4. Construction of a Ferroptosis-Related Nine-lncRNA Signature for Predicting Prognosis and Immune Response in Hepatocellular Carcinoma.
Xu Z; Peng B; Liang Q; Chen X; Cai Y; Zeng S; Gao K; Wang X; Yi Q; Gong Z; Yan Y
Front Immunol; 2021; 12():719175. PubMed ID: 34603293
[TBL] [Abstract][Full Text] [Related]
5. Oncogenic signaling pathway-related long non-coding RNAs for predicting prognosis and immunotherapy response in breast cancer.
Li H; Liu H; Hao Q; Liu X; Yao Y; Cao M
Front Immunol; 2022; 13():891175. PubMed ID: 35990668
[TBL] [Abstract][Full Text] [Related]
6. Six-long non-coding RNA signature predicts recurrence-free survival in hepatocellular carcinoma.
Gu JX; Zhang X; Miao RC; Xiang XH; Fu YN; Zhang JY; Liu C; Qu K
World J Gastroenterol; 2019 Jan; 25(2):220-232. PubMed ID: 30670911
[TBL] [Abstract][Full Text] [Related]
7. Identification of a five-long non-coding RNA signature to improve the prognosis prediction for patients with hepatocellular carcinoma.
Zhao QJ; Zhang J; Xu L; Liu FF
World J Gastroenterol; 2018 Aug; 24(30):3426-3439. PubMed ID: 30122881
[TBL] [Abstract][Full Text] [Related]
8. Glycolysis-associated lncRNAs identify a subgroup of cancer patients with poor prognoses and a high-infiltration immune microenvironment.
Ho KH; Huang TW; Shih CM; Lee YT; Liu AJ; Chen PH; Chen KC
BMC Med; 2021 Feb; 19(1):59. PubMed ID: 33627136
[TBL] [Abstract][Full Text] [Related]
9. Comprehensive analysis of N6-methyladenosine -related long non-coding RNAs and immune cell infiltration in hepatocellular carcinoma.
Yu ZL; Zhu ZM
Bioengineered; 2021 Dec; 12(1):1708-1724. PubMed ID: 33955330
[TBL] [Abstract][Full Text] [Related]
10. Identification of Hypoxia-Related Prognostic Signature and Competing Endogenous RNA Regulatory Axes in Hepatocellular Carcinoma.
Tang Y; Zhang H; Chen L; Zhang T; Xu N; Huang Z
Int J Mol Sci; 2022 Nov; 23(21):. PubMed ID: 36362375
[TBL] [Abstract][Full Text] [Related]
11. Identification of a DNA damage repair-related LncRNA signature for predicting the prognosis and immunotherapy response of hepatocellular carcinoma.
Huang F; Zhang C; Yang W; Zhou Y; Yang Y; Yang X; Guo W; Wang B
BMC Genomics; 2024 Feb; 25(1):155. PubMed ID: 38326754
[TBL] [Abstract][Full Text] [Related]
12. A somatic mutation-derived LncRNA signatures of genomic instability predicts the prognosis and tumor microenvironment immune characters in hepatocellular carcinoma.
Jin C; Zhao JS; Huang XQ; Yang XZ; Niu FY; Lin JR; Ma L; Shi YX; Li XS; Jiang P; Gao S; Li F; Song Y
Hepatol Int; 2022 Oct; 16(5):1220-1233. PubMed ID: 35947245
[TBL] [Abstract][Full Text] [Related]
13. Development of a novel immune-related lncRNA prognostic signature for patients with hepatocellular carcinoma.
Li R; Jin C; Zhao W; Liang R; Xiong H
BMC Gastroenterol; 2022 Nov; 22(1):450. PubMed ID: 36344926
[TBL] [Abstract][Full Text] [Related]
14. Potential biomarkers for the prognosis and treatment of HCC immunotherapy.
Li H; He Q; Zhou GM; Wang WJ; Shi PP; Wang ZH
Eur Rev Med Pharmacol Sci; 2023 Mar; 27(5):2027-2046. PubMed ID: 36930502
[TBL] [Abstract][Full Text] [Related]
15. Comprehensive analysis of cuproptosis-related lncRNAs in immune infiltration and prognosis in hepatocellular carcinoma.
Liu C; Wu S; Lai L; Liu J; Guo Z; Ye Z; Chen X
BMC Bioinformatics; 2023 Jan; 24(1):4. PubMed ID: 36597032
[TBL] [Abstract][Full Text] [Related]
16. M6A-related lncRNAs predict clinical outcome and regulate the tumor immune microenvironment in hepatocellular carcinoma.
Chen B; Yang Z; Lang Z; Tao Q; Zhang R; Zhan Y; Xu X; Zhu K; Zheng J; Yu Z; Yu S
BMC Cancer; 2022 Aug; 22(1):867. PubMed ID: 35941582
[TBL] [Abstract][Full Text] [Related]
17. LncRNA SNHG7 accelerates the proliferation, migration and invasion of hepatocellular carcinoma cells via regulating miR-122-5p and RPL4.
Yang X; Sun L; Wang L; Yao B; Mo H; Yang W
Biomed Pharmacother; 2019 Oct; 118():109386. PubMed ID: 31545291
[TBL] [Abstract][Full Text] [Related]
18. Identification of Ferroptosis-related molecular model and immune subtypes of hepatocellular carcinoma for individual therapy.
Long S; Chen Y; Wang Y; Yao Y; Xiao S; Fu K
Cancer Med; 2023 Jan; 12(2):2134-2147. PubMed ID: 35841206
[TBL] [Abstract][Full Text] [Related]
19. A novel lncRNA RP11-386G11.10 reprograms lipid metabolism to promote hepatocellular carcinoma progression.
Xu K; Xia P; Gongye X; Zhang X; Ma S; Chen Z; Zhang H; Liu J; Liu Y; Guo Y; Yao Y; Gao M; Chen Y; Zhang Z; Yuan Y
Mol Metab; 2022 Sep; 63():101540. PubMed ID: 35798238
[TBL] [Abstract][Full Text] [Related]
20. A novel classification of HCC basing on fatty-acid-associated lncRNA.
Xu Y; Yu X; Zhang Q; He Y; Guo W
Sci Rep; 2022 Nov; 12(1):18863. PubMed ID: 36344648
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
